Friedemann Rabe, Sefonias Getachew, Clara Yolanda Stroetmann, Nikolaus Christian Simon Mezger, Tewodros Yalew Gebremariam, Bereket Berhane, Alex Mremi, Blandina Theophil Mmbaga, Pauline Boucheron, Valerie McCormack, Pablo Santos, Adamu Addissie, Eva Johanna Kantelhardt
{"title":"可疑乳腺病变病理诊断时间:埃塞俄比亚五家医院的一项基于机构的研究。","authors":"Friedemann Rabe, Sefonias Getachew, Clara Yolanda Stroetmann, Nikolaus Christian Simon Mezger, Tewodros Yalew Gebremariam, Bereket Berhane, Alex Mremi, Blandina Theophil Mmbaga, Pauline Boucheron, Valerie McCormack, Pablo Santos, Adamu Addissie, Eva Johanna Kantelhardt","doi":"10.1002/ijc.35436","DOIUrl":null,"url":null,"abstract":"<p><p>Most breast cancer (BC) patients in sub-Saharan Africa are diagnosed at advanced stages. The World Health Organization's Global Breast Cancer Initiative Pillar II has a benchmark to diagnose BC within 2 months of the first contact with a health care provider (HCP). In this study, we interviewed 345 women who received a diagnostic workup of a suspicious breast lesion (eventually diagnosed as benign or malignant) at five Ethiopian hospitals in 2022. We assessed the length of the diagnostic journey encompassing the pre-contact interval between the first experience of symptoms and the first HCP visit, and the post-contact interval between HCP visit and diagnostic pathology procedures. We used negative binomial regression models to identify factors influencing these time intervals. The median pre-contact interval was 2.8 months (interquartile range [IQR] 0.5-9.8). The median post-contact interval was 1.7 months (IQR 0.6-3.9). Regarding the post-contact interval, 55% of patients received their pathologic diagnosis within the recommended 2 months after the first HCP visit and met the Global Breast Cancer Initiative's benchmark. Increased travel times, limited social support, and consulting multiple HCPs before seeking pathology evaluation prolonged post-contact intervals. Older patients (>45 years) and those referred for pathology evaluation during the initial HCP visit experienced shorter post-contact intervals. Of all 345 women, 39% were diagnosed with BC. The relatively low proportion of women diagnosed within the recommended time frame makes it evident that increased awareness for BC, easily accessible diagnostic services, and specific training for HCPs are essential for the timely diagnosis of BC in Ethiopia.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals.\",\"authors\":\"Friedemann Rabe, Sefonias Getachew, Clara Yolanda Stroetmann, Nikolaus Christian Simon Mezger, Tewodros Yalew Gebremariam, Bereket Berhane, Alex Mremi, Blandina Theophil Mmbaga, Pauline Boucheron, Valerie McCormack, Pablo Santos, Adamu Addissie, Eva Johanna Kantelhardt\",\"doi\":\"10.1002/ijc.35436\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Most breast cancer (BC) patients in sub-Saharan Africa are diagnosed at advanced stages. The World Health Organization's Global Breast Cancer Initiative Pillar II has a benchmark to diagnose BC within 2 months of the first contact with a health care provider (HCP). In this study, we interviewed 345 women who received a diagnostic workup of a suspicious breast lesion (eventually diagnosed as benign or malignant) at five Ethiopian hospitals in 2022. We assessed the length of the diagnostic journey encompassing the pre-contact interval between the first experience of symptoms and the first HCP visit, and the post-contact interval between HCP visit and diagnostic pathology procedures. We used negative binomial regression models to identify factors influencing these time intervals. The median pre-contact interval was 2.8 months (interquartile range [IQR] 0.5-9.8). The median post-contact interval was 1.7 months (IQR 0.6-3.9). Regarding the post-contact interval, 55% of patients received their pathologic diagnosis within the recommended 2 months after the first HCP visit and met the Global Breast Cancer Initiative's benchmark. Increased travel times, limited social support, and consulting multiple HCPs before seeking pathology evaluation prolonged post-contact intervals. Older patients (>45 years) and those referred for pathology evaluation during the initial HCP visit experienced shorter post-contact intervals. Of all 345 women, 39% were diagnosed with BC. The relatively low proportion of women diagnosed within the recommended time frame makes it evident that increased awareness for BC, easily accessible diagnostic services, and specific training for HCPs are essential for the timely diagnosis of BC in Ethiopia.</p>\",\"PeriodicalId\":180,\"journal\":{\"name\":\"International Journal of Cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ijc.35436\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ijc.35436","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals.
Most breast cancer (BC) patients in sub-Saharan Africa are diagnosed at advanced stages. The World Health Organization's Global Breast Cancer Initiative Pillar II has a benchmark to diagnose BC within 2 months of the first contact with a health care provider (HCP). In this study, we interviewed 345 women who received a diagnostic workup of a suspicious breast lesion (eventually diagnosed as benign or malignant) at five Ethiopian hospitals in 2022. We assessed the length of the diagnostic journey encompassing the pre-contact interval between the first experience of symptoms and the first HCP visit, and the post-contact interval between HCP visit and diagnostic pathology procedures. We used negative binomial regression models to identify factors influencing these time intervals. The median pre-contact interval was 2.8 months (interquartile range [IQR] 0.5-9.8). The median post-contact interval was 1.7 months (IQR 0.6-3.9). Regarding the post-contact interval, 55% of patients received their pathologic diagnosis within the recommended 2 months after the first HCP visit and met the Global Breast Cancer Initiative's benchmark. Increased travel times, limited social support, and consulting multiple HCPs before seeking pathology evaluation prolonged post-contact intervals. Older patients (>45 years) and those referred for pathology evaluation during the initial HCP visit experienced shorter post-contact intervals. Of all 345 women, 39% were diagnosed with BC. The relatively low proportion of women diagnosed within the recommended time frame makes it evident that increased awareness for BC, easily accessible diagnostic services, and specific training for HCPs are essential for the timely diagnosis of BC in Ethiopia.
期刊介绍:
The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories:
-Cancer Epidemiology-
Cancer Genetics and Epigenetics-
Infectious Causes of Cancer-
Innovative Tools and Methods-
Molecular Cancer Biology-
Tumor Immunology and Microenvironment-
Tumor Markers and Signatures-
Cancer Therapy and Prevention